PMID: 46761Apr 1, 1975

Cultivation of leukemic human bone marrow cells in diffusion chambers implanted into normal and irradiated mice

Blood
L Fauerholdt, N Jacobsen

Abstract

In order to elucidate the question of whether the maturation defect in vivo in acute leukemia is due to environmental or cellular factors, we have cultured human leukemic cells in a nonleukemic milieu, i.e., diffusion chambers implanted into the abdominal cavity of normal and irradiated mice. For each harvest, the cell count was measured and differential counts and the number of peroxidase-positive cells determined. The cell number decreased with time, without significant difference between culture in irradiated (500 rads) and normal mice. The blast cells succeeded only in developing distorted promyelocytes and myelocytes. There was a general pattern of increase in the number of peroxidase-positive cells. The study supports the concept that acute myeloid leukemia (AML) is a disturbance of cellular maturation due to cellular rather than environmental defects.

Related Concepts

Abdominal Cavity
Promyelocytes
Acute Leukemia
Peroxidases
Blast Cell
Biologic Development
Acute Myeloid Leukemia Pathway
Hairy Cell Leukemia
Cell Differentiation Process
Cell Division Phases

Related Feeds

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.